Loading
NASDAQHealthcareBiotechnology
Latest quote
$21.86
−$0.93 · -4.08%
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Previous close
$21.86
−$0.93 · -4.08%
Pre-market
$21.99
+$0.13 · +0.59%
Sep 11, 6:05 AM ET
Regular session · ET · Market data may be delayed.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Day range
Current $21.86
52-week range
Current $21.86
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
70
Bullish
Risk
36
Moderate Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Day range
Current $21.86
52-week range
Current $21.86
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 22.5M USD | 45.56M USD | 14.09M USD | 102.69M USD | — |
| Cost of goods sold | 59K USD | — | — | — | — |
| Gross profit | 22.44M USD | 45.56M USD | 14.09M USD | 102.69M USD | — |
| Research and development | 141.83M USD | 151.41M USD | 159.42M USD | 86.74M USD | 28.97M USD |
| Selling, general, and administrative | 106.3M USD | 70.45M USD | 37.63M USD | 19.51M USD | 5.68M USD |
| Operating expenses | 248.13M USD | 221.85M USD | 197.06M USD | 106.25M USD | 34.98M USD |
| Interest income | 27.59M USD | 16.88M USD | 10.22M USD | — | — |
| Interest expense | — | — | 6.8M USD | 287K USD | 411K USD |
| Depreciation and amortization | 220K USD | 113K USD | 49K USD | 9K USD | 5K USD |
| Operating income | −225.68M USD | −176.29M USD | −182.97M USD | −3.56M USD | −34.98M USD |
| Net income | −203.82M USD | −241.6M USD | −176.94M USD | −22.63M USD | −41.79M USD |
Company facts updated Sep 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Capital Group U.S. Small and Mid Cap ETFCGMM16.41M0.48%3.44B USD0.51%$31.73-1.00%
iShares Biotechnology ETFIBB13.92M0.13%10.3B USD0.44%$202.64-1.39%
Vanguard Health Care ETFVHT5.09M0.02%20.9B USD0.09%$311.27-0.65%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.39M0.09%1.59B USD0.43%$35.29-1.23%
iShares ESG Aware MSCI USA Small-Cap ETFESML1.17M0.04%2.8B USD0.17%$53.41-1.02%
Fidelity MSCI Health Care Index ETFFHLC700.88K0.02%3.48B USD0.08%$80.46-0.63%
Global X - Guru Index ETFGURU677.91K1.10%61.63M USD0.75%$68.51-1.09%
VistaShares Target 15 DRUKMacro Distribution ETFDRKY579.03K3.10%18.9M USD0.95%$21.37-0.95%Capital Group U.S. Small and Mid Cap ETFCGMMiShares Biotechnology ETFIBBVanguard Health Care ETFVHTFidelity Fundamental Small-Mid Cap ETFFFSMiShares ESG Aware MSCI USA Small-Cap ETFESMLFidelity MSCI Health Care Index ETFFHLCGlobal X - Guru Index ETFGURUVistaShares Target 15 DRUKMacro Distribution ETFDRKYAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
